NIKA PHARMACEUTICALS, INC (NKPH) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2269 MERRIMACK VALLEY AVENUE HENDERSON, NV 89044 |
| State of Incorp. | CO |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 19,596 | 864 | 399 | 1,611 | |||
| Cash and cash equivalents | 19,596 | 864 | 399 | 1,611 | |||
| Total current assets: | 19,596 | 864 | 399 | 1,611 | |||
| Noncurrent Assets | |||||||
| TOTAL ASSETS: | 19,596 | 864 | 399 | 1,611 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Debt | 101,745 | ||||||
| Due to related parties | ✕ | ✕ | 18,180 | 10,518 | |||
| Total current liabilities: | 101,745 | 18,180 | 10,518 | ||||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 13,500 | 10,518 | |||||
| Due to related parties | ✕ | ✕ | 13,500 | 10,518 | |||
| Total noncurrent liabilities: | 13,500 | 10,518 | |||||
| Total liabilities: | 101,745 | 18,180 | 24,018 | 10,518 | |||
| Equity | |||||||
| Equity, attributable to parent, including: | (82,149) | (17,316) | (23,619) | (8,907) | |||
| Preferred stock | 1,000 | 10,000 | |||||
| Common stock | 87,609 | 87,609 | 13,203 | 13,203 | |||
| Additional paid in capital | 3,229,489 | 3,220,489 | 114,877 | 114,877 | |||
| Retained earnings (accumulated deficit) | (3,400,247) | 3,335,414 | 151,699 | (136,987) | |||
| Other undisclosed equity, attributable to parent | (6,670,828) | (303,398) | |||||
| Total equity: | (82,149) | (17,316) | (23,619) | (8,907) | |||
| TOTAL LIABILITIES AND EQUITY: | 19,596 | 864 | 399 | 1,611 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | ||||||
| Gross profit: | ||||||
| Operating expenses | (64,833) | (3,183,715) | (14,712) | (8,907) | ||
| Operating loss: | (64,833) | (3,183,715) | (14,712) | (8,907) | ||
| Nonoperating income (Real Estate Investment Partnership Revenue) | ||||||
| Loss from continuing operations: | (64,833) | (3,183,715) | (14,712) | (8,907) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (14,712) | (8,907) | |
| Other undisclosed net income (loss) | 6,367,430 | |||||
| Net income (loss): | (64,833) | 3,183,715 | (14,712) | (8,907) | ||
| Other undisclosed net income (loss) attributable to parent | (6,367,430) | |||||
| Net loss available to common stockholders, diluted: | (64,833) | (3,183,715) | (14,712) | (8,907) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (64,833) | 3,183,715 | (14,712) | (8,907) | ||
| Comprehensive income (loss): | (64,833) | 3,183,715 | (14,712) | (8,907) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (64,833) | 3,183,715 | (14,712) | (8,907) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.